SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending as the community rallies around its potential as the next big meme coin on the Solana blockchain, drawing comparisons to $SHIB.X and $DOGE.X. Many community members express strong conviction and highlight the supportive community, while others emphasize its association with the $PUMP.X ecosystem.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies behind this Solana-based crypto, highlighting its locked liquidity and burned tokens. Discussions mention the coin's potential, joke-meta pioneer status, and growing community, with some comparing it to other meme coins like $SHIB.X and emphasizing its presence on Jupiter Exchange's strict list.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as traders assess the potential impact of recent economic data, including a weaker-than-expected jobs report, on future Federal Reserve policy. Community discussions revolve around the likelihood of rate cuts and their potential effects, while some express concerns about market manipulation and the reliability of economic data. A court decision impacting tariffs is also adding to the uncertainty.

HarryPotterObamaSonic10Inu (Ticker: BITCOIN) is a endgame of crypto-assets (0 Tax). BITCOIN incentivizes the creation of novel and entertaining meme content. With ownership renounced and Liquidity locked, our robust growing community has taken the lead; we have successfully completed a full audit, an NFT collection, and are exploring partnerships with other tokens in the space, a one-of-a -kind website, and one-of-a-kind merchandise and ecommerce site in the works based on the legendary meme that inspired BITCOIN's creation. Our goal is to create an ecosystem for active community members to meet, collaborate, and share our rich lore (the archive of our token's storied history) with the world.

hposI0iETH

Bitcoin's recent activity has spurred discussions around its potential to outperform traditional stocks, with community members analyzing chart patterns and debating future price movements. Some users are comparing it to other cryptocurrencies and memecoins, while others are discussing broader narratives around tokenization and the potential impact of regulatory approvals. The community also seems to be focused on the relationship between Bitcoin and specific altcoins.

Flare is a blockchain for building applications that are interoperable with other blockchains and the internet.  ## What is Flare (FLR)?  Flare is an EVM-based Layer 1 blockchain designed to allow developers to build applications that are interoperable with blockchains and the internet. By providing decentralized access to high-integrity data, Flare enables new use cases and monetisation models.   ## What makes Flare unique?  Flare's native interoperability protocols, the State Connector and the FTSO are secured by the network itself, allowing it to reliably deliver data from a wide variety of off-chain sources in a decentralized way.   The Flare Time Series Oracle delivers highly-decentralized price and data feeds to dapps on Flare, without relying on centralized providers.   The State Connector protocols enable information, both from other blockchains and the internet to be used securely, scalably and trustlessly with smart contracts on Flare.  Risk is minimized by building this decentralized data infrastructure natively into the blockchain, powered by a large number of independent data providers.  By incentivizing sets of independent providers to query, acquire, and process data without relying on single, centralized sources, Flare’s core protocols can facilitate the development of interoperable dapps with a broad range of potential innovative use cases.   ## What is the Flare (FLR) token used for?  FLR is the native token used for payments, transaction fees to prevent spam attacks and staking in validator nodes. FLR can also be wrapped into an ERC-20 variant, WFLR. WFLR tokens serve various functions; they can be delegated to FTSO data providers, for example, or staked to participate in governance. These two uses are not mutually exclusive and do not prevent the tokens from being used in other EVM-compatible dapps and smart contracts on Flare.  Wrapped FLR (WFLR) can be minted by depositing native FLR tokens into a smart contract and withdrawing the newly minted

Spark Token

Spark Token ($FLR.X) is trending as the community discusses its potential, particularly its connection to XRP and the possibility of staking integration on Crypto.com. Recent news highlights adoption by Revolut Learn & Earn and a Google Cloud mention, fueling speculation about its long-term potential and comparisons to Solana's growth.

Pump.fun

$PUMP.X is trending as users discuss its potential as a memecoin launchpad on Solana, highlighting its revenue model and community growth. Community members are actively discussing entry points, price targets, and whether it can reach the levels of coins like $DOGE.X. Some are pointing to potential catalysts, like exchange listings and upcoming events, that could drive further momentum.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad ($GIGA.X) is trending as community members discuss its potential within the meme coin sector, drawing comparisons to other popular coins and highlighting its strong community. Recent social media activity, including a YouTuber meeting the real Gigachad, may be contributing to the increased attention. Some traders are also watching its correlation to Solana ($SOL.X) for potential movement.

In a crypto world of meme coins kekistan is it's home.  Is goes back to mid 2000s being a 4chan community. The birth place of Pepe the frog, This community  has brought other communities together  to support something  in crypto and real life. We have rebranded a token. Bringing fun and happy environment. Were actually  the 3rd place in our communities life.  The first place being  home and family  time. The 2nd  is workplace. And were the 3rd place at the end of the day we are there they relax and enjoy themselves

Kekistan

Kekistan ($KEK.X) is trending as community members rally around the meme-based cryptocurrency, celebrating its origins from 4chan and its potential for significant growth. The community emphasizes the power of memes and the vision of a decentralized, meme-driven future. Many reference the coin's history and connection to internet culture.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, fueled by significant institutional investments, with Galaxy Digital's recent acquisitions drawing considerable attention. The community is buzzing about potential price targets and the emergence of new projects and memecoins built on the Solana blockchain, such as $WAGMI.X and $UPDOG.X. Discussions also involve signals, predictions, and overall bullish sentiment surrounding Solana's potential within the broader crypto market.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX6900 is trending as community members discuss its potential for significant gains, drawing comparisons to past meme coin and stock surges.  Enthusiasts highlight the strength and dedication of the community, with some suggesting that it could outperform traditional assets and even "flip the stock market". There's also excitement around potential listings and growing mainstream recognition.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street issued mixed calls on scPharmaceuticals on Monday after MannKind said it would buy the former in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met.&nbsp;The deal represents a 31% premium to scPharma’s last closing price before the announcement.After the news, Craig-Hallum pulled back its rating on scPharmaceuticals, shifting it from ‘Buy’ to ‘Hold’ and setting a price target of $6.&nbsp;Craig-Hallum noted that shareholders are entitled to receive $5.35 in cash per share, along with the potential to receive up to an additional $1 in cash per share from future milestone payments and the firm expects a majority of the CVR value to be paid out over time.Maxim Group also downgraded scPharmaceuticals to ‘Hold’ from ‘Buy’ following the acquisition agreement under the same terms.By contrast, H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with a $9 price target, saying the acquisition strengthens MannKind’s revenue base and expands its reach into cardiorenal medicine. The firm described the price paid as “very reasonable.”The acquisition gives&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">MannKind access to Furoscix</a>, scPharma’s FDA-approved on-body infuser delivering furosemide to treat fluid overload in patients with chronic heart failure and chronic kidney disease.&nbsp;MannKind estimates Furoscix has a total addressable U.S. market of more than $10 billion.scPharma has been expanding its commercial footprint, reporting $27.8 million in net sales for the first half of 2025, a 96% increase year over year, driven by a larger sales force, growth in nephrology, and new integrated delivery network accounts.&nbsp;Its Furoscix ReadyFlow Autoinjector is expected to be filed for FDA approval in the third quarter of 2025, potentially reducing administration time from five hours to less than 10 seconds.The deal is expected to close in the fourth quarter of 2025 pending regulatory approval.&nbsp;At closing, MannKind will also repay and retire scPharma’s credit facility and revenue-sharing obligations to Perceptive, totaling about $81 million if completed by Sept. 30, 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment was ‘extremely bullish’ for scPharmaceuticals with ‘extremely high’ message volume, while sentiment for MannKind was ‘bullish’ with ‘high’ message volume.One user remarked that it was unusual to see a smaller company like MannKind buying a larger one, calling the deal “bizarro territory.”<stembedurl>https://stocktwits.com/Kuka/message/626521368</stembedurl>Another user noted that the acquisition would eliminate scPharmaceuticals’ heavy sales and marketing costs, saying they were beginning to appreciate the efficiency gains MannKind could achieve by folding those operations into its own.<stembedurl>https://stocktwits.com/oneyedjacks/message/626485594</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SCPH">scPharmaceuticals’ stock</a> has risen nearly 56% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined nearly 40% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind (MNKD) said it would buy scPharmaceuticals (SCPH) in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met. (Photo credit: Getty Images)

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

Equity

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth">said</a>.The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MannKind</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/SCPH">SCPH stock</a> jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.While MNKD stock is down by 36% this year, SCPH stock is up by 37%.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y">Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

scPharmaceuticals's Earnings Outlook

Buy Rating Affirmed: scPharmaceuticals's Revenue Surge and Product Development Promise

Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals (SCPH Research Report) yesterday and set a price target of $20.00. Na...

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization

FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance...

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The firm's products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

SCPH
scPharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SCPH News

SCPH scPharmaceuticals Inc